MabGenesis

Executive Summary

MabGenesis is a Tokyo-based preclinical biopharmaceutical startup founded in 2020, specializing in the discovery of first-in-class and best-in-class therapeutic monoclonal antibodies for both human and companion animal health. The company leverages its proprietary MOURA antibody libraries and IMPACT isolation technology to generate 100% species-specific antibodies, addressing critical needs in oncology, zoonotic diseases, and veterinary conditions (dogs and cats). Despite being at an early stage with no disclosed funding rounds or valuation, MabGenesis differentiates itself by targeting both human and veterinary markets, a niche that could capture significant value. The company’s technology platform is designed to overcome cross-reactivity issues, potentially speeding development timelines. However, as a preclinical private company with limited public information, the risk profile is high. Key upcoming catalysts include potential IND-enabling studies and partnership announcements that could validate the platform and provide growth capital.

Upcoming Catalysts (preview)

• Q1 2027Completion of IND-enabling studies for lead candidate in oncology30% success
• H2 2026Strategic partnership or licensing deal for companion animal antibody pipeline40% success
• Q4 2026Presentation of preclinical data at major oncology or veterinary conference60% success